» Authors » Schayan Yousefian

Schayan Yousefian

Explore the profile of Schayan Yousefian including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 70
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Maatz H, Lindberg E, Adami E, Lopez-Anguita N, Perdomo-Sabogal A, Cocera Ortega L, et al.
Nat Cardiovasc Res . 2025 Feb; PMID: 39994453
Myocarditis, characterized by inflammatory cell infiltration, can have multiple etiologies, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or, rarely, mRNA-based coronavirus disease 2019 (COVID-19) vaccination. The underlying cellular...
2.
Lutz R, Grunschlager F, Simon M, Awwad M, Bauer M, Yousefian S, et al.
Nat Commun . 2024 Nov; 15(1):10396. PMID: 39613747
The long-term consequences of cancer and its therapy on the patients' immune system years after cancer-free survival remain poorly understood. Here, we present an in-depth characterization of the bone marrow...
3.
Kobbe G, Bruggemann M, Baermann B, Wiegand L, Trautmann H, Yousefian S, et al.
N Engl J Med . 2024 Nov; 391(13):1217-1226. PMID: 39589371
The development of a fatal, clonal, autonomously proliferating CD4-CD8- chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after a patient received treatment with tisagenlecleucel for relapsed primary...
4.
Derigs P, Schubert M, Dreger P, Schmitt A, Yousefian S, Haas S, et al.
Leukemia . 2024 Aug; 38(11):2419-2428. PMID: 39192036
Third-generation chimeric antigen receptor T cells (CARTs) for relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL) may improve efficacy compared to second-generation CARTs due to their enhanced CAR design. We...
5.
Bageritz J, Krausse N, Yousefian S, Leible S, Valentini E, Boutros M
G3 (Bethesda) . 2023 Jul; 13(10). PMID: 37494060
Single-cell RNA sequencing has become an important method to identify cell types, delineate the trajectories of cell differentiation in whole organisms, and understand the heterogeneity in cellular responses. Nevertheless, sample...
6.
Schubert M, Schmitt A, Huckelhoven-Krauss A, Neuber B, Kunz A, Waldhoff P, et al.
J Hematol Oncol . 2023 Jul; 16(1):79. PMID: 37481608
Background: Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalating, phase-1/2...
7.
Heigwer F, Scheeder C, Bageritz J, Yousefian S, Rauscher B, Laufer C, et al.
Cell Syst . 2023 Apr; 14(5):346-362.e6. PMID: 37116498
Cellular and organismal phenotypes are controlled by complex gene regulatory networks. However, reference maps of gene function are still scarce across different organisms. Here, we generated synthetic genetic interaction and...
8.
Demel U, Wirth M, Yousefian S, Zhang L, Isaakidis K, Donig J, et al.
Haematologica . 2022 Sep; 108(2):555-567. PMID: 36134453
Aberrant activity of the SUMOylation pathway has been associated with MYC overexpression and poor prognosis in aggressive B-cell lymphoma (BCL) and other malignancies. Recently developed small-molecule inhibitors of SUMOylation (SUMOi)...
9.
Yousefian S, Musillo M, Bageritz J
Methods Mol Biol . 2022 Aug; 2540:93-111. PMID: 35980574
The fly Drosophila is a versatile model organism that has led to fascinating biological discoveries. In the past few years, Drosophila researchers have used single-cell RNA-sequencing (scRNA-seq) to gain insights...
10.
Demel U, Boger M, Yousefian S, Grunert C, Zhang L, Hotz P, et al.
J Clin Invest . 2022 May; 132(9). PMID: 35499080
Activated SUMOylation is a hallmark of cancer. Starting from a targeted screening for SUMO-regulated immune evasion mechanisms, we identified an evolutionarily conserved function of activated SUMOylation, which attenuated the immunogenicity...